Forbes April 1, 2024
Wegovy, a popular weight-loss drug in high demand, can now be covered by Medicare and Medicaid provided patients using it have heart disease.
A recent trial that enrolled over 17,000 participants demonstrated that Wegovy reduced the risk of heart attack, stroke and cardiovascular disease by 20% compared to placebo. The participants were overweight or obese and had established cardiovascular disease but not diabetes. The landmark trial was the first to show that a class of obesity drugs could provide long-term benefits to heart health in those who are overweight or obese.
Semaglutide, the active ingredient in Wegovy, mimics the naturally occurring hormone glucagon-like peptide-1 which delays the emptying of food from the stomach and acts on hunger centers in the...
Today's Sponsors
Today's Sponsor